cyrilzakka/clinical-trials huggingface dataset:
the Efficacy of Giomer Versus Sodium Fluoride in the Treatment of Hypersensitivity

to solve the problem of hypersensitivity, I will use two different materials ( Giomer versus Sodium Fluoride) and compare between their effects in reliving the symptoms

The dentin hypersensitivity is characterized by short, sharp pain which can be detected by several methods. The problem is very annoying for the patients and making them seek for effective rapid treatment.

It can affect several teeth in one area of the mouth or only one specific tooth. Careful diagnosis of such condition necessitates precise differentiation of its signs and symptoms from the other causes of tooth sensitivity which may be resulted from dental caries, micro leakage, cracked tooth or fractured restoration. There are two well-known ways to reduce the discomfort of the hypersensitivity either by blocking the exposed dentinal tubules by occluding materials or use some depolarizing agents that reducing the excitability of the intra dental nerves.Most of the desensitizing agents reduces the dentin hypersensitivity by its own way and each one has different long lasting effect. But there are some drawbacks that appeared with their use. Fluoride based agents were appeared in 90's but it was clarified that their high concentration irritated the odontoblasts. Furthermore, the oxalates and potassium nitrate were introduced to treat the hypersensitivity effectively but their effects did not persist for a long period of time.

Sodium fluoride varnish is one from the most commonly used desensitizing agent and its efficacy was approved in many studies. The Giomer varnish containing surface pre-reactive glass particles (S-PRG) is a light-cured protective varnish and it was introduced to promote prolonged protection for the hypersensitive dentin.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged from 18 to 40 years.
* No gender restriction.
* Patients should have pain score in the visual analog scale two or more.
* Patients must have at least one sensitive tooth in one of four quadrants.

Exclusion Criteria:

* Patients with active carious lesions.
* Needing restorative treatment.
* Receiving periodontal treatment.
* Taking desensitizing treatment in the last 6 months.
* Taking anti-inflammatory drugs.
* Pregnant patients.
* Smokers.
Effect of Laser and Sclerotic Agent in the Treatment of Oral Granuloma

Pyogenic granuloma is a common tumor-like growth of the oral cavity considered to be non-neoplastic in nature. They usually present as a reactive lesion occur in response to chronic and recurring tissue injury, in which capillaries are very prominent commonly seen arising from interdental gingiva. Pyogenic granuloma may occur in all ages, with a peak age of incidence in the second decade of life, more common in young adult females, possibly because of vascular effects of female hormones.

Oral PG can be treated by conservative excision. Local irritants or the source of trauma must be eliminated to minimize the risk of recurrence. Although, surgical excision is considered a simple procedure, it might be complicated by several complications such as intraoperative bleeding, and postoperative infection that might delay the healing of the wound. Other treatment modalities such as laser, injection of sclerosing agents have been used.

Laser has proven to be an effective therapy for oral soft tissue pathologies. Moreover, its ability to perform precise incisions, better hemostasias, and less invasive procedures with less discomfort to patients have made it a preferred treatment option for several soft tissue lesions.

Sclerotherapy has been proposed as an effective method of treatment for pyogenic granuloma. Their mechanism of action is endothelial injury, inflammation, thrombosis, fibrosis, and final lesion destruction. Polidocanol is a widely used nonionic detergent sclerosant that was first developed as an anesthetic. It acts through endothelial overhydration, vascular injury, and closure.

Eligibility Criteria:
Inclusion Criteria:

* All the subjects were principally diagnosed based on history and clinical features such as oral pyogenic granuloma are selected for this study. Radiographic evaluation was also done to rule out any bony involvement.
* The sizes of participants' lesions were not less than 5 mm. • Age \> 18 years

Exclusion Criteria:

* Patients were excluded if they had uncontrolled diabetes, renal diseases, coagulation disorders or were allergic to any of the sclerosing drug constituents. Immune-compromised patients and pregnant and lactating women were also excluded from the study.
Asthma Outcomes in Children After Adenotonsillectomy

The aim of the study is to assess the effect of adenotonsillectomy on level of asthma control in preschool children with obstructive sleep apnea.

Asthma is the most common chronic disease in children ,in children younger than six years it is difficult to diagnose asthma as pulmonary function tests can not be performed reliably before the age six .

Wheezing is one of the main symptoms of asthma. Young children with multiple trigger wheeze as activities ,laughing and crying are more likely to have asthma compared with episodic (viral) wheeze.

The mainstay of asthma control is daily administration of inhaled corticosteroids, long acting beta2 agonists and avoid exposure of asthma triggers as seasonal allergens and environmental pollution particularly tobacco smoke exposure.

Recent studies have found asthma to be associated with overlapping comorbidities including gastroesophageal reflux,obesity and obstructive sleep apnea.This studies have introduced therapeutic strategies aimed at improving asthma control by management of these coexisting conditions.

Pathophysiological feature of childhood obstructive sleep apnea is presence of increased airway inflammation promoting of hypertrophy of upper airway adenotonsillar tissues .

The latter promotes increased pharyngeal resistance thus predispose the upper airway to episodically collapse and cause fragmented sleep that characterize obstructive sleep apnea.

Surgically adenotonsillectomy is the first line of therapy in childhood obstructive sleep apnea and has favorable outcomes ,including improvements of respiratory sleep disturbances and in reducing markers of asthma and reduction in the use of asthma therapies.

Eligibility Criteria:
Inclusion Criteria:

* preschool children (2_5)years with criteria of bronchial asthma with obstructive sleep apnea regardless sex.

Exclusion Criteria:

* patients with other disorders that may cause obstructive sleep apnea as cranio facial syndrome , Down syndrome, cerebral palsy ,obesity,sickle cell disease, low birth weight.
* Any associated medical comorbidity that contraindicates general anesthesia.
Environmental Risk Factors of Mesh Infection After Abdominal Wall Hernia Repair

Mesh infection is the main complication in abdominal hernia repair. In case of infection, a conservative management of mesh is not always possible. The removal of the mesh (occurring in 5.1% to 8% of wall hernia repair) increases the risk of recurrence and surgical morbidity.

Within our digestive surgery department (CHRU de Nancy), an infection rate of 10.7% (32 cases out of 298 patients with wall hernia repair) was observed between January 2016 and December 2018. This rate is higher than those usually described in the literature.

Several studies have identified predictors of mesh infection and explantation after abdominal wall hernia repair. The influence of the operating environment (temperature, hygrometry, pressure, number of people present, etc.) has, to our knowledge, never been studied.

If the risk of prosthesis infection is influenced by one or more of these extrinsic characteristics, it is possible to act on these practices to reduce this risk.

The main purpose of this study is to identify the characteristics specific to the intervention and the operating environment associated with mesh infection after abdominal wall hernia reconstruction

It's a prospective, mono-centric study carried out on a cohort of patients followed in the digestive surgery department of the CHRU of Nancy

All patients who underwent a wall hernia repair between 28/12/2017 and 28/12/2020 in the digestive and general surgery department of the CHU of Nancy were included.

During the operative time, the nurses have to fill a survey with characteristics specific to the intervention and the operating environment.

Patients in this study have been followed for at least one year at the Nancy CHRU in order to be aware of the occurence of mesh infection and surgery for mesh explantation.

Eligibility Criteria:
Inclusion Criteria:

* All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020

Exclusion Criteria:

* Emergency surgery
* Laparoscopic
* Pregnancy
* Adults under legal guardianship
Identifying Oxytocin Deficiency in Adults With Pituitary Disease

This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that:

1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control.
2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.


Eligibility Criteria:
Inclusion Criteria:

* AVD Group:

Adults 18-65 years old Arginine-vasopressin deficiency Stable pituitary hormone replacement

* Healthy Control Group Adults 16-65 years old

Exclusion Criteria for all participants:

* History of pulmonary embolism, deep vein thrombosis, breast/endometrial cancer, stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral artery disease
* Pregnancy or breastfeeding within last 8 weeks
* Any significant illness or condition that the investigator determines could interfere with study participation, data collection, or safety
CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC

The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity and efficacy in the combined treatment with intensity-modulated radiation therapy (IMRT) and carbon ion (C12) boost. Primary endpoint is mucositis ≥ CTC°3, secondary endpoints are local control, disease-free survival, and toxicity. Planned accrual of the trial includes 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Treatment consists of 24 GyE carbon ions (8 fractions) and 50 Gy IMRT (2.0 Gy/ fraction).

Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/ carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.

Methods/ design:

The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity in the combined treatment with intensity-modulated radiation therapy (IMRT) and carbon ion (C12) boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (2.0 Gy/ fraction).

Study objectives:

Incidence of mucositis ≥ CTC°3 will be assessed as the primary endpoint of the trial, local control, disease-free survival, toxicity (incl. mucositis CTC °I-II and late toxicity at 3 years post RT)

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed or surgically removed malignant tumour of the salivary glands (head and neck)
* Inoperable tumour
* G2/3
* Macroscopic or microscopic residual tumour (R2/ R1) or
* ≥T3/T4 or
* perineural invasion (Pn+)
* written informed consent
* pts aged 18 - 80 years
* effective contraception for pts in childbearing age (\<12 months post beginning of menopause)

Exclusion Criteria:

* Prior radio- or chemotherapy for tumours of the head and neck
* Other previous malignancy within the past 5 years except prior, adequately treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
* Significant neurological or psychiatric condition including dementia or seizures or other serious medical condition prohibiting the patient's participation in the trial by judgement of the investigators
* Legal incapacity or limited legal capacity
* Positive serum/ urine beta-HCG/ pregnancy
* Drug abuse
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases

1. Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks
2. Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks

Eligibility Criteria:
Inclusion Criteria:

* Type II diabetes mellitus
* Subjects who have not been taking any oral hypoglycemic agent within 8 weeks from screening or who have been taking metformin monotherapy at the same dose for more than 8 weeks before screening
* Subjects with 6.5%≤HbA1c≤9.0% at screening
* Subjects with 20kg/m2≤BMI≤40kg/m2 at screening

Exclusion Criteria:

* Type I diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
* AST \> upper normal range\*3
* Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Subjects who experienced hypersensitivity reaction against DPP-4 inhibitors, thiazolidinediones
* Pregnant women
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.


Eligibility Criteria:
Inclusion Criteria:

* Outpatient with primary Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) GSP plus at least one of the following comorbid DSM-IV anxiety disorders:

  * panic disorder with agoraphobia
  * obsessive compulsive disorder
  * major depressive disorder
  * generalized anxiety disorder
* Score on LSAS \> 50
* Score on MADRS \< 25

Exclusion Criteria:

* Any other primary AXIS-I diagnosis
* Criteria for alcohol/substance abuse/dependence
* History (Hx) of bipolar disorder, schizophrenia or other psychotic disorder
* A comorbid Axis II cluster A personality disorder
* Current increased risk of concomitant suicide
* Allergy/previous intolerance during an adequate trial (50mg/day for minimum of 4 weeks) of sertraline
* Participation in any clinical trial 30 days prior to entering the study
* Unable to tolerate being free of/shows signs of withdrawal from benzodiazepines for 4 weeks
* Hx of seizures
* Thyroid problems
The Effect of Eye Masks and Earplugs In Intensive Care Unit Patients

This study was planned as a randomized controlled and experimental study to evaluate the effect of eye masks and earplugs on sleep quality and vital signs in intensive care patients.

The research will be conducted with 60 patients hospitalized in the intensive care units of a state hospital. Research data will be collected with a questionnaire, vital signs follow-up form, insomnia severity index, and Richards-Campbell Sleep Quality Scale. Patients will be divided into intervention and control groups. Eye mask and ear plugs will be applied to the intervention group for 3 days, and the control group will receive routine care. The study will be terminated after 3 days of follow-up for each patient.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and over,
* Able to answer all questions and communicate,
* Those who agreed to participate in the research
* Being in the category of insomnia, moderate insomnia, or severe insomnia according to the insomnia severity index,
* Not sedating
* Not connected to a ventilator
* No hearing problem
* Glasgow Coma Score of 15

Exclusion Criteria:

* Connecting to the ventilator during operation
* Sedation during the study
* Wanting to leave the research during the study
* Being in the intervention group and removing the eye patch or earplug during sleep
* GCS falling below 15
Aortic Calcium: Epidemiology and Progression -- Ancillary to MESA

To study the epidemiology of aortic calcium.

BACKGROUND:

Aortic calcium measured by computed tomography occurs earlier in life than other subclinical (that is, asymptomatic) markers of cardiovascular disease (CVD), shows a wide range, and is common in women. The large size of the aorta and relative lack of image artifact from motion make it ideal for radiographic quantitative imaging. This study is ancillary to and coordinated with the Multi-Ethnic Study of Atherosclerosis (MESA), a large prospective epidemiologic study investigating multiple subclinical CVD measures and CVD risk factors. Subclinical measures in MESA include coronary calcium, carotid ultrasound, cardiac magnetic resonance imaging, and the ankle/brachial blood pressure index. The extensive CVD risk factor measurements include both traditional risk factors and newer measures such as inflammatory and genetic markers.

DESIGN NARRATIVE:

This ancillary study will determine the epidemiology of aortic calcium in 2000 randomly selected (from 6500 total) MESA participants. Questions to be addressed include predictors of aortic calcium progression; associations of aortic calcium and aortic calcium progression with other subclinical CVD measures, CVD risk factors, and demographics; and the prognostic significance of aortic calcium. The project has three primary specific aims: 1) to predict the cross-sectional aortic calcium burden as a function of other subclinical CVD measures and CVD risk factors; 2) to predict aortic calcium progression as a function of other subclinical CVD measures and CVD risk factors, and 3) to predict aortic calcium progression as a function of progression of selected subclinical CVD measures and CVD risk factors. The two secondary specific aims are 1) to contrast the results of the three primary specific aims for men vs. women, and for four major ethnic groups (White, Hispanic, Black, and Asian); and 2) to provide a database for future evaluation of whether aortic calcium and/or aortic calcium progression independently predict subsequent myocardial infarction, stroke, and other CVD events.

Eligibility Criteria:
Participation in the original MESA Study
Effects of Upper Airway Muscle Training on Obstructive Sleep Apnea Severity

The purpose of this study is to evaluate the effect of Asate Silent Sleep Training on obstructive sleep apnea (OSA) severity in patients with mild to moderate OSA. The Asate Silent Sleep Training is a muscle strengthening program that uses exercise equipment (a musical instrument that is based on the didgeridoo). The equipment is connected to an application, which provides instruction on how to perform the strengthening exercises, measures the sound produced by the musical instrument, which enables the app to provide feedback on whether the individual should blow less or more and also tracks adherence to the strengthening program.


Eligibility Criteria:
Inclusion Criteria:

* Age 21 to 50
* Diagnosed by a physician with mild to moderate OSA, based upon interpretation of data recorded on a take home sleep study
* Body mass index \< 30 kg/m2
* Mild to moderate OSA, AHI of 5-30

Exclusion Criteria:

1. Apnea hypopnea index on overnight sleep study \> 30 per hour
2. Currently practices didgeridoo
3. Consumes more than 2 alcoholic beverages per day
4. History of chronic lung disease (e.g., COPD, asthma)
5. Oral maxillofacial issue or craniofacial musculoskeletal conditions
6. Any treatment for OSA (current or past)
7. Mobile device use frequency \< once per week
8. Homelessness
9. No reliable transportation to assessment sessions
10. Planned social/family/employment obligations that would limit participant from engaging in Asate Silent Sleep training during the intervention period
11. Significant upper extremity weakness/paralysis or pain limiting ability to hold the Medical Didgeridoo
12. Uncorrected low vision or blindness
13. Deafness
14. No Internet connection/Chrome browser/mobile devices with iOS and Android
15. No USB port in computer
16. Pregnancy
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Eligibility Criteria:
Inclusion Criteria:

* • ≥ 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast

Exclusion Criteria:

* 18 years of age

  * Prisoners
  * Pregnant or breastfeeding